Drug Information

Drug General Information
Drug ID
D04BFC
Former ID
DNCL003452
Drug Name
CC-292
Drug Type
Small molecular drug
Indication Chronic lymphocytic leukaemia [ICD10:C91] Phase 2 [532375]
Company
Celgene
Structure
Download
2D MOL

3D MOL
Formula
C22H22FN5O3
InChI
InChI=1S/C22H22FN5O3/c1-3-20(29)25-16-5-4-6-17(13-16)26-21-19(23)14-24-22(28-21)27-15-7-9-18(10-8-15)31-12-11-30-2/h3-10,13-14H,1,11-12H2,2H3,(H,25,29)(H2,24,26,27,28)
InChIKey
KXBDTLQSDKGAEB-UHFFFAOYSA-N
PubChem Compound ID
59174488
PubChem Substance ID
140509429, 141135748, 163515657, 163771476, 172121850, 185998871, 198434377, 198939026, 210275710, 210281369, 223366168, 223390703, 224756386, 225848303, 226926901, 242651825, 247731407, 251910621, 252110281, 252160838, 252214916, 252449031, 252451608, 252470556
Target and Pathway
Target(s) Tyrosine-protein kinase BTK Target Info Modulator [532375]
KEGG Pathway NF-kappa B signaling pathway
Osteoclast differentiation
Platelet activation
B cell receptor signaling pathway
Fc epsilon RI signaling pathway
Primary immunodeficiency
PANTHER Pathway B cell activation
Pathway Interaction Database Fc-epsilon receptor I signaling in mast cells
BCR signaling pathway
FAS (CD95) signaling pathway
Class I PI3K signaling events
EPO signaling pathway
PathWhiz Pathway Fc Epsilon Receptor I Signaling in Mast Cells
Reactome MyD88:Mal cascade initiated on plasma membrane
Regulation of actin dynamics for phagocytic cup formation
DAP12 signaling
FCERI mediated Ca+2 mobilization
MyD88 deficiency (TLR2/4)
IRAK4 deficiency (TLR2/4)
RHO GTPases Activate WASPs and WAVEs
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
WikiPathways Kit receptor signaling pathway
MyD88:Mal cascade initiated on plasma membrane
Signaling by the B Cell Receptor (BCR)
DAP12 interactions
B Cell Receptor Signaling Pathway
TSLP Signaling Pathway
Regulation of toll-like receptor signaling pathway
IL-5 Signaling Pathway
References
Ref 532375Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013 Aug;346(2):219-28.
Ref 532375Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013 Aug;346(2):219-28.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.